A. Rubino

First name
A.
Last name
Rubino
Whittaker, H., Nordon, C., Rubino, A., Morris, T., Xu, Y., de Nigris, E., et al. (2022). Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent postdiagnosis COPD exacerbations and mortality: EXACOS-UK health care data study. Thorax. http://doi.org/10.1136/thorax-2022-219039
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Martinez, D., Lei, A., et al. (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997
Whittaker, H., Rubino, A., Mullerova, H., Morris, T., Varghese, P., Xu, Y., et al. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591
Rivero-Ferrer, E., Olesen, M., Plana, E., Aguado, J., Saigi-Morgui, N., Rubino, A., et al. (2022). Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. http://doi.org/10.1007/s40261-022-01120-2
Rubino, A., Roskell, N., Tennis, P., Mines, D., Weich, S., & Andrews, E. (2007). Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. Bmj. http://doi.org/10.1136/bmj.39041.445104.BE
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Lei, A., Daoud, S., et al. (2021). A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s301624